Algert Global LLC reduced its holdings in shares of Phreesia, Inc. (NYSE:PHR – Free Report) by 41.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,827 shares of the company’s stock after selling 18,640 shares during the quarter. Algert Global LLC’s holdings in Phreesia were worth $611,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently modified their holdings of the company. Champlain Investment Partners LLC boosted its holdings in shares of Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after acquiring an additional 97,847 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Phreesia by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 447,239 shares of the company’s stock valued at $10,193,000 after purchasing an additional 16,112 shares during the period. Intech Investment Management LLC purchased a new stake in Phreesia in the third quarter worth approximately $316,000. Quest Partners LLC grew its position in Phreesia by 5,361.8% in the 3rd quarter. Quest Partners LLC now owns 31,296 shares of the company’s stock worth $713,000 after purchasing an additional 30,723 shares during the period. Finally, GSA Capital Partners LLP raised its stake in Phreesia by 418.3% during the 3rd quarter. GSA Capital Partners LLP now owns 49,553 shares of the company’s stock valued at $1,129,000 after buying an additional 39,993 shares during the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.
Phreesia Price Performance
NYSE:PHR opened at $21.03 on Friday. The stock has a market cap of $1.21 billion, a PE ratio of -11.68 and a beta of 0.94. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03. The business’s 50-day simple moving average is $20.43 and its two-hundred day simple moving average is $21.86. Phreesia, Inc. has a 52 week low of $14.55 and a 52 week high of $29.16.
Analyst Upgrades and Downgrades
Several analysts recently commented on the company. Robert W. Baird lifted their price objective on Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $23.00 price target on shares of Phreesia in a research report on Friday, September 27th. DA Davidson reissued a “buy” rating and issued a $32.00 price objective on shares of Phreesia in a report on Thursday, September 5th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of Phreesia in a research report on Thursday, September 5th. Finally, JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.42.
View Our Latest Report on Phreesia
Insider Activity at Phreesia
In other Phreesia news, CEO Chaim Indig sold 5,295 shares of the stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $23.25, for a total transaction of $123,108.75. Following the completion of the transaction, the chief executive officer now owns 1,223,736 shares of the company’s stock, valued at $28,451,862. This represents a 0.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Balaji Gandhi sold 3,502 shares of Phreesia stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $23.25, for a total value of $81,421.50. Following the completion of the sale, the chief financial officer now directly owns 98,578 shares in the company, valued at $2,291,938.50. This trade represents a 3.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 29,997 shares of company stock valued at $667,943. Corporate insiders own 5.80% of the company’s stock.
Phreesia Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
Read More
- Five stocks we like better than Phreesia
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- ETF Screener: Uses and Step-by-Step Guide
- MarketBeat Week in Review – 11/25 – 11/29
- Insider Selling Explained: Can it Inform Your Investing Choices?
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Want to see what other hedge funds are holding PHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phreesia, Inc. (NYSE:PHR – Free Report).
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.